Allergy Therapeutics

Historical price data

Allergy Therapeutics is a mission-driven company committed to transforming lives by pioneering convenient, disease-modifying immunology treatments. Its core achievement is the development of a proprietary, aluminium-free adjuvant platform that enables ultra-short-course allergy vaccines, dramatically improving patient adherence and access. The company's strategy leverages its established commercial operations in Europe, particularly Germany, as a foundation while advancing a late-stage pipeline targeting major allergic indications like grass and peanut allergy, positioning it for significant growth in the expanding immunotherapy market.

Bencard Adjuvant Systems (BAS): A proprietary, aluminium-free adjuvant platform designed to modulate immune responses, enabling ultra-short-course allergy immunotherapy regimens with 4-6 injections over 3-5 weeks.

Competes against larger AIT players like ALK and Stallergenes, as well as novel food allergy specialists like DBV and Aimmune. Its key differentiators are its aluminium-free, ultra-short-course regimens and vertically integrated European commercial model.